Correlation analysis of serum IL1RL1, DAPPER5, and MFGF with poor prognosis in patients with heart failure

Background: To explore the predictive value of the combined effect of serum Interleukin-1 Receptor-like 1 (IL1RL1), dishevelled-associated protein 5 (DAPPER5), and Metabolic fibroblast growth factor (MFGF) on poor prognosis in patients with heart failure with preserved ejection fraction (HFpEF). Methods: The study group comprised 382 HFpEF patients diagnosed and treated at this facility between July 2023 and August 2025. The control group consisted of 382 additional healthy individuals who were physically examined at the same hospital during the same time period. Patients were monitored for a year following their release from therapy. The poor prognosis group comprised patients who had adverse cardiovascular events throughout the follow-up period, while the good prognosis group included the remaining patients. Each research participant’s serum levels of IL1RL1, DAPPER5, and MFGF were assessed using an enzyme-linked immunosorbent assay. Using multivariate logistic analysis, the factors influencing the poor prognosis of HFpEF patients were investigated. A receiver operating characteristic (ROC) curve was developed to evaluate the predictive value of serum IL1RL1, DAPPER5, and MFGF, both independently and in combination, for a poor prognosis in patients with HFpEF. Results: While the study group’s serum DAPPER5 level was lower than the control group’s, the study group’s serum IL1RL1 and MFGF levels were higher. There was a statistically significant change (P